<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525144</url>
  </required_header>
  <id_info>
    <org_study_id>EGB-MCI</org_study_id>
    <nct_id>NCT04525144</nct_id>
  </id_info>
  <brief_title>EGb 761 in the Syndrome of MCI With Concomitant CVD</brief_title>
  <official_title>Evaluating the Role of EGb 761 in the Syndrome of Mild Cognitive Impairment With Concomitant Cerebrovascular Disease (MCI + CVD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Neuroscience Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Willmar Schwabe GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Neuroscience Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed&#xD;
      clinical drug for patients with MCI + CVD. This study is an open label 52-weeks study in&#xD;
      subjects who have both MCI (based on the Petersen criteria and Albert MS criteria) and CVD.&#xD;
      Eligibility for enrolment will be assessed initially at a screening visit, which is to occur&#xD;
      within 42 days of baseline. 134 male and female subjects will participate and 67 of the 134&#xD;
      will receive the drug. Subjects will be randomized to the EGB 761 arm and control arm in a&#xD;
      1:1 ratio using a block randomization method in groups of 4 subjects using an automated&#xD;
      randomization software.&#xD;
&#xD;
      EGb 761 has been demonstrated to be useful in improving cognitive and global clinical&#xD;
      outcomes in patients with cognitive impairment or dementia, when administered at a daily&#xD;
      dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of&#xD;
      action. The study will allow generating data in an Asian and multi-racial population and&#xD;
      allows physicians to offer clinically efficacious and alternative treatment for patients with&#xD;
      MCI + CVD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-Cognitive 13 (ADAS-Cog 13)</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Dementia Rating Sum of Boxes Scores (CDR-SOB)</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Cognitive Assessment Tool (VCAT)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mild Behavioural Impairment Checklist (MBI-C)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Cerebrovascular Disease</condition>
  <arm_group>
    <arm_group_label>Tebonin Forte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120mg, twice a day, 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tebonin Forte</intervention_name>
    <description>Dietary supplement: Gingko biloba EGb 761</description>
    <arm_group_label>Tebonin Forte</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS&#xD;
             criteria&#xD;
&#xD;
          -  Patients who have a Global Clinical Dementia Rating Score of 0.5&#xD;
&#xD;
          -  Patients aged 45 to 85 years at study entry&#xD;
&#xD;
          -  Patients who are literate and able to complete the cognitive evaluations in the&#xD;
             opinion of the investigators&#xD;
&#xD;
          -  Patients with the presence of CVD, defined as the presence of white matter&#xD;
             hyperintensities (WMH) of Fazekas grade 2 or 3 on MRI brain imaging (done up to 12&#xD;
             months prior to recruitment) or CT scans for patients contraindicated from MRI scans&#xD;
&#xD;
          -  Patients who provide written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants should not be receiving antidepressants, antipsychotics, benzodiazepines,&#xD;
             acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally,&#xD;
             contraindications for EGb 761 as given in the local prescribing information/Summary of&#xD;
             Product Characteristics (SmPC) should be observed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagaendran Kandiah</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Neuroscience Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Wang</last_name>
    <phone>(65) 6357 7635</phone>
    <email>joanna.wang.s@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Neuroscience Institute</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Wang</last_name>
      <phone>(65) 63577546</phone>
      <email>ctru@nni.com.sg</email>
    </contact>
    <investigator>
      <last_name>Nagaendran Kandiah, MRCP;FAMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012 Jun;46(6):716-23. doi: 10.1016/j.jpsychires.2012.03.003. Epub 2012 Mar 27.</citation>
    <PMID>22459264</PMID>
  </reference>
  <reference>
    <citation>Müller WE, Eckert A, Eckert GP, Fink H, Friedland K, Gauthier S, Hoerr R, Ihl R, Kasper S, Möller HJ. Therapeutic efficacy of the Ginkgo special extract EGb761(®) within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. World J Biol Psychiatry. 2019 Mar;20(3):173-189. doi: 10.1080/15622975.2017.1308552. Epub 2017 May 2. Review.</citation>
    <PMID>28460580</PMID>
  </reference>
  <reference>
    <citation>Gavrilova SI, Preuss UW, Wong JW, Hoerr R, Kaschel R, Bachinskaya N; GIMCIPlus Study Group. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. Int J Geriatr Psychiatry. 2014 Oct;29(10):1087-95. doi: 10.1002/gps.4103. Epub 2014 Mar 16.</citation>
    <PMID>24633934</PMID>
  </reference>
  <reference>
    <citation>Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, Napryeyenko O; GOTADAY Study Group. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2011 Nov;26(11):1186-94. doi: 10.1002/gps.2662. Epub 2010 Dec 7.</citation>
    <PMID>21140383</PMID>
  </reference>
  <reference>
    <citation>Yuan Q, Wang CW, Shi J, Lin ZX. Effects of Ginkgo biloba on dementia: An overview of systematic reviews. J Ethnopharmacol. 2017 Jan 4;195:1-9. doi: 10.1016/j.jep.2016.12.005. Epub 2016 Dec 7. Review.</citation>
    <PMID>27940086</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

